Zai Lab Announces the First Listing of VYVGART® (efgartigimod alfa injection) and Other Updates in China's National Reimbursement Drug List | Business

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec 12, 2023--

Related Keywords

China ,Hong Kong ,Massachusetts ,United States ,Taiwan ,Macau ,Shanghai ,William Liang ,Josh Smiley ,Christine Chiou Lina Zhang ,Shaun Maccoun Xiaoyu Chen ,Zai Lab Limited ,China National Healthcare Security Administration ,Glaxosmithkline ,Exchange Commission ,Zai Lab Forward ,National Reimbursement Drug List ,Zai Lab ,Paratek Pharmaceuticals Inc ,National Medical Products Administration ,Lab Limited ,Reimbursement Drug List ,National Healthcare Security Administration ,Chief Commercial Officer ,Chief Operating Officer ,Myasthenia Gravis ,Greater China ,Paratek Pharmaceuticals ,Ovarian Cancer ,Private Securities Litigation Reform Act ,Investor Relations ,Business Wire ,Business ,